Olivier Adotévi

4.5k citations
100 papers · 2.4k indexed · h-index 30

Olivier Adotévi

94 papers receiving 2.4k citations

Peers

Olivier Adotévi
Comparison fields: 5 of 95
  • Immunology 1.4k
  • Oncology 1.3k
  • Biotechnology 127
  • Cancer Research 192
  • Endocrinology 60
Replace Sathibalan Ponniah with:
Sathibalan Ponniah United States
J. Louise Lines United States
Hanifa Bouzourène Switzerland
Hans de Haard Belgium
Takanori So Japan
Andrew M. Jackson United Kingdom
Francisco J. Cueto Spain
Jernej Godec United States
Vafa Shahabi United States
Caroline Aspord France
Olivier Adotévi relative to Sathibalan Ponniah United States Sathibalan Ponniah's profile →
Citations per field
00.5×4.1×
Sathibalan Ponniah · 1×
Citations per year

Countries citing papers authored by Olivier Adotévi

Since Specialization
Citations

This map shows the geographic impact of Olivier Adotévi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Adotévi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Adotévi more than expected).

Fields of papers citing papers by Olivier Adotévi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Adotévi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Adotévi. The network helps show where Olivier Adotévi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Olivier Adotévi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olivier Adotévi Line = papers co-authored together Olivier Adotévi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20240
3 20240
4 20225
5 20224
6 202241
7 202113
8 202134
9 202031
10 202022
11 201933
12 201936
13 201914
14 201868
15 20165
16 201516
17 201247
18 201276
19
Les lymphocytes T‐CD8 : rôle dans l‘immunosurveillance et l‘immunothérapie antitumorale
20036
20 2000107

About Olivier Adotévi

Olivier Adotévi is a scholar working on Immunology, Oncology and Biotechnology, having authored 100 papers that have together received 2.4k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (52 papers), Cancer Immunotherapy and Biomarkers (36 papers), Immune Cell Function and Interaction (31 papers), CAR-T cell therapy research (26 papers), Virus-based gene therapy research (9 papers), T-cell and B-cell Immunology (9 papers), Immune cells in cancer (8 papers) and RNA Interference and Gene Delivery (7 papers). The work is most often cited by research in Immunology (1.4k citations), Oncology (1.3k citations) and Biotechnology (127 citations). Olivier Adotévi has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include Éric Tartour, Yann Godet, Christophe Borg, Wolf H. Fridman, Magalie Dosset, Jeanne Galaine, Christophe Borg, Nacilla Haicheur, Romain Loyon and Cécile Badoual. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The EMBO Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026